REG-Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

* Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits(1) as of June 30, 2026 * Cash runway guidance remains unchanged from July 30, 2026(2) * Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026 * Key highlights from the first half of 2026 and recent Company updates * Management to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update.